A radiopharmaceutical company has received a key authorization for its new headquarters in Indianapolis. SpectronRx, a contract development and manufacturing organization, has received a materials license from the U.S. Nuclear Regulatory Commission, which will allow it to handle special nuclear material in chemical or physical form.
SpectronRx specializes in theranostics, which are therapies that use a small amount of radioactive material to both diagnose and treat different diseases at the cellular level. The company was originally founded in South Bend before moving to Indy.
The company acquired the Indy facility in 2019 and has invested several million dollars into it, according to a spokesperson. SpectronRx says it started with just three full-time and one part-time employees in Indy and the license will allow it to add up to 75 employees over the next 18 months.
The company says receiving the materials license from the NRC will also allow it to expand its staff. The Indy facility was acquired by SpectronRx in late 2019 and a spokesperson says several million dollars have been invested in
“Securing Nuclear Regulatory Commission materials licensing for our new headquarters and additional staff is a significant milestone for the growth of SpectronRx,” John Zehner, chief executive officer of SpectronRx, said in a news release. “We now have the necessary approvals to scale our newly opened 60,000 square foot Indianapolis facility. This is great news for both patients and the State of Indiana alike, as it means a bigger pipeline for life-saving therapies and more jobs for medical professionals specializing in radiopharmaceuticals.”
The company says it also has plans to expand into the European Union.
In addition to radiopharmaceuticals, SpectronRx has also been helping with the COVID-19 pandemic. Last June, the company received an Emergency Use Authorization from the U.S. Food and Drug Administration for its coronavirus test kit.